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Abstract 
Nucleation-dependent polymerization f/3-amyloid peptide, the major component of plaques in patients with Alzheimer's 
disease, is significantly accelerated by crosslinking through Advanced Glycation End-products (AGEs) in vitro. During the 
polymerization process, both nucleus formation and aggregate growth are accelerated by AGE-mediated crosslinking. 
Formation of the AGE-crosslinked amyloid peptide aggregates could be attenuated by the AGE-inhibitors Tenilsetam, 
aminoguanidine and carnosine. These experimental data, and clinical studies, reporting a marked improvement in cognition 
and memory in Alzheimer's disease patients after Tenilsetam treatment, suggest that AGEs might play an important role in 
the etiology or progression of the disease. Thus AGE-inhibitors may generally become a promising drug class for the 
treatment of Alzheimer's disease. 
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1. Introduction 
Alzheimer's disease is a progressive dementia f- 
fecting a large proportion of the aging population. 
Histological hallmarks of the disease are widespread 
neuronal cell death and the formation of amyloid 
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amyloid precursor protein; CSF, cerebrospinal fluid; NPY, neu- 
ropeptide Y; AD, Alzheimer's disease 
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plaques and neurofibrillary tangles. The major pro- 
teinaceous component of the amyloid deposits which 
accumulate xtracellularly in the Alzheimer's disease 
brain, is the /3/A4-amyloid peptide. This 39-42 
amino acid peptide consists of 28 extramembranal 
amino acids plus 11 to 14 residues of the hydropho- 
bic transmembrane domain of its precursor, the amy- 
loid /3 precursor protein, APP (for reviews, see 
[1-31). 
Genetic and biochemical evidence suggest hat the 
/3-amyloid peptide is important in the etiology or 
progression of the disease. Genetic studies have linked 
familial cases of early-onset Alzheimer's disease to 
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the APP-locus on chromosome 21, where mutations 
in the APP-gene may influence APP-processing, /3- 
amyloid peptide concentration or its aggregation pa- 
rameters [4,5]. Further, two major biochemical mech- 
anisms by which /3-amyloid peptide or its aggregates 
may be involved in neuronal cell death have been 
proposed: direct neurotoxicity and indirect, immune 
system mediated neurotoxicity of the peptide aggre- 
gates. Firstly, several studies have demonstrated that 
/3-amyloid peptide is both toxic to neurons in primary 
culture and to clonal cell lines [6-8]. Interestingly, 
the neurotoxicity of the peptide seems to increase 
with its aggregation state, since preaggregation f the 
synthetic peptide at concentrations above 50 /zg/ml 
produces a maximal toxic effect [9]. The induction of 
oxidative stress [10], apoptosis [11] and ion channel 
formation [12] are the proposed interrelated mecha- 
nisms mediating this direct toxicity. 
Secondly, the /3-amyloid peptide is suggested to 
stimulate an indirect, immune mediated neurotoxicity 
by activation of resting microglia to brain 
macrophages by proteinous plaque deposits. This re- 
sults in the concomitant release of oxygen free radi- 
cals, NO, cytokines and complement proteins, which 
may damage surrounding neurons through 'bystander 
lysis' [13-15]. 
The aggregation of /3-amyloid peptide, therefore, 
may be critical for neuronal cell death in Alzheimer's 
disease via the stimulation of either direct and indi- 
rect neurotoxicity. This suggests that, changes in 
aggregation rate and plaque formation are likely to be 
important for the onset and progression of the dis- 
ease. Aggregation of the /3-amyloid peptide has been 
proposed to follow a nucleation-dependent poly- 
merization process, consisting of two distinctive steps, 
an initial slow nucleus formation, followed by a rapid 
growth phase [16]. The formation of a nucleus is a 
reversible process dependent on the concentration f
the peptide monomer, thus it is likely that the initia- 
tion of this process at a sub-threshold peptide concen- 
tration may only be started by irreversible covalent 
crosslinking of the monomers. A universal extracellu- 
lar crosslinking of long-lived proteins by AGEs oc- 
curs following the initial reaction of a protein amino 
group with a monosaccharide, such as glucose or 
fructose [33,38]. Recently, immunohistochemical 
studies on post mortem tissue have identified AGEs 
as major components of amyloid plaques [17,18]. In 
vitro studies with synthetic fl-amyloid peptide sug- 
gest that AGE-amyloid seeds can trap soluble pep- 
tides and accelerate plaque formation [18]. In addi- 
tion, AGE-crosslinking inhibitors, such as Tenilse- 
tam, have been shown in clinical trials to reverse 
impairments of cognitive function in patients with 
Alzheimer's disease [19]. 
Our aim in this study was to investigate the extent, 
to which different monosaccharides accelerate both 
steps of amyloid plaque formation, nucleation and 
growth. Secondly, we investigated the ability of 
AGE-inhibitors to attenuate these reactions. A posi- 
tive result would posit a biochemical mechanism for 
their beneficial effect and promise a new approach to 
rationale drug design for the treatment of Alzheimer' s 
disease. 
2. Methods 
2.1. Peptide preparation 
/3-amyloid peptide (1-40) was purchased from 
Auspep (Melboume, Australia) or synthesized on a 
Zinsser simultaneous multiple peptide synthesizer us- 
ing Fmoc-protection and DIC/HOBT activating 
chemistry with routine double coupling steps. Depro- 
tection was achieved by TFA/an iso l /e than-  
dithiol/H20 (93/5/2.5/2.5).  After precipitation i
ether, peptide was redissolved in 10% formic acid 
and purified on a preparative HPLC RP-C 18 column. 
Purity and molecular weight of the peptide was con- 
firmed by comparison with commercial (1-40) /3- 
amyloid peptide standards by analytical HPLC and 
mass spectrometry. 
2.2. Incubation of peptides with sugars 
Stock solutions of peptides were dissolved in H20 
at a concentration of 1 mg/ml.  For AGE-cross- 
linking experiments, they were incubated in 0.5 ml 
microtubes or 1 ml cuvettes at a concentration f 250 
~g/ml  (60/xM) in 50 mM sodium phosphate buffer 
pH 7.9 at 40°C or 50°C in the dark for the times 
indicated. NaN 3 (0.01% w/v)  was added to prevent 
microbiological growth. In long term experiments, 
water was added every 12 h to compensate for sol- 
vent evaporation. 
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2.3. Quantification of peptide by polyacrylamide gel 
electrophoresis and image analysis 
2.6. Determination of [3-sheet content of [3-amyloid 
peptide aggregates by Thioflavin T 
Prior to electrophoresis, samples were incubated in 
4% SDS, 0.01% Bromophenol Blue in 0.1 M Tris, 
pH 8.9, for 30 min at 42°C. Samples were separated 
in a 16.5% polyacrylamide gel, topped with a 6% 
spacer and a 1% stacking gel using a tricine buffer 
system (pH 8.3) which allows separation of peptides 
as small as 2 kDa [37]. Gels were fixed in 50% 
methanol/10% acetic acid for 30 min, stained with 
0.025% Coomassie Brilliant Blue G-250 in 10% acetic 
acid for 30 min and destained with 10% acetic acid 
overnight. Coomassie Brilliant Blue has been shown 
to be the most accurate protein determination assay 
for glycated and AGE-modified proteins [45]. Gels 
were photographed and protein bands quantified us- 
ing an Apple Colorone scanner and the NIH Image 
1.57 software. The lag time (the end of nucleus 
formation) was defined as the time, after which more 
than 10% of the monomer had disappeared. 
2.4. Quantification of peptide oligomers > 30 kDa 
by ultrafiltration 
/3-sheet content of peptide aggregates after ultrafil- 
tration (see Section 2.4) was measured with Thioflavin 
T as described in [18]. Briefly, 30 /xl of sample 
containing about 7.5 /zg of peptide was ultrafiltrated, 
the supernatant resuspended and added to 1 ml 3 /.zM 
Thioflavin T solution in 50 mM sodium phosphate 
pH 6.0. After gentle vortexing, emission at 480 nm 
(excitation at 450 nm) was measured in a Spex 
Fluoromax fluorescence spectrometer with slits set at 
1 nm. Values are expressed as arbitrary units (AU). 
2.7. Bradford protein assay 
Total peptide or protein content in solution was 
measured by the Bradford assay. The sample (con- 
taining up to 7.5 /xg of peptide) was added to 400/zl 
Bradford reagent (0.1% Coomassie Blue in 10% 
H3PO 4, 5% ethanol). After 5 rain, optical density at 
595 nm was measured in a LKB UV-Vis spectro- 
photometer. 
/3-Amyloid peptide oligomers > 30 kDa were sep- 
arated by ultrafiltration through a 30 kDa membrane. 
Briefly, 30 /xl of 60 /zM peptide solution containing 
6.25 /zg of peptide was transferred into a Schleicher 
and Schuell Centrix UF cartridge and centrifuged at 
13 000 X g for 2 min. After addition of 20 /xl of 
PBS, the centrifugation step was repeated. The re- 
tained supernatant was resuspended in 2 X 20 ~1 
PBS and transferred into a second tube. Protein con- 
tent was determined in both supernatant and filtrate 
by the Bradford assay (see Section 2.7). 
2.5. Counting of peptide aggregates with a cell 
counter 
/3-Amyloid peptide aggregates were counted in a 
Scherf Casy cell counter equipped with a 150 /xm 
capillary. 10 /xl of the samples were diluted in 10 ml 
0.9% NaC1 and 200 /xl of the solution counted in 
triplicate. The cursor were set at 6 and 24 /xm and 
the number of peptide aggregates and their total 
volume within this interval was determined. 
2.8. Western blot 
1 /zg of /3-amyloid peptide was removed from the 
incubation mixture and incubated in sample buffer 
(4% SDS, 0.01% Bromophenol Blue in 0.1 M Tris, 
pH 8.9) for 30 min at 42°C prior to electrophoresis. 
Samples were separated in a 16.5% polyacrylamide 
gel, topped with a 6% spacer and a 1% stacking gel 
using a tricine buffer system (pH 8.3) which allows 
separation of peptides as small as 2 kDa [37]. After 
electrophoresis, proteins were transferred onto a 
nitrocellulose sheet. The nitrocellulose sheet was 
blocked for 1 h with PBS containing 6% BSA, 1% 
FCS and 0.05% Tween 20. After incubation for 2 h 
with an fl-amyloid peptide (1-40) rabbit antibody (a 
gift from Dr. Stauffenbiel, Sandoz AG) in a dilution 
of 1:2000, alkaline phosphate linked anti rabbit IgG 
(Boehringer, diluted 1:2000 in PBS) was added and 
incubated for 1 h. The Western blot was developed 
with DTNB in glycine buffer (pH 10.4) and photo- 
graphed. 
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3. Results 
3.1. Assays for monitoring crosslinking and aggrega- 
tion of/3-amyloid peptide 
Nucleation-dependent polymerization of amyloid 
peptide in solution leads to an equilibrium with two 
components: insoluble amyloid peptide aggregates 
and a low concentration of soluble monomer in the 
supernatant [16]. Among different APP derived /3- 
amyloid peptides and fragments, /3-amyloid peptide 
(1-40) has sufficient kinetic solubility at micromolar 
concentrations, and was therefore used in all experi- 
ments shown below. Fructose was used in addition to 
glucose in AGE-crosslinking experiments, because it 
has been shown to be abundant in brain and to 
crosslink proteins up to ten times faster than glucose 
[21]. The experiments were performed with concen- 
trations of reactants and temperatures well above the 
physiological levels. However, this enabled us to 
accelerate the process of plaque formation, which 
takes decades in vivo [28], to be monitored in vitro in 
a reasonable time period. 
Formation of /3-amyloid aggregates from soluble 
monomer was measured by four different assays. The 
loss of soluble /3-amyloid peptide monomer was 
monitored by SDS gel electrophoresis, Coomassie 
Blue staining and image analysis of the 4.2 kDa 
/3-amyloid peptide band in the gel. Protein content of 
peptide oligomers > 30 kDa were quantified in fil- 
trate and supernatant after ultrafiltration by the Brad- 
ford (Coomassie Blue) protein assay. Coomassie Blue 
binding has been shown to be the less influenced 
assay for protein determination by glycation and 
AGE-modification [45]. In agreement with this study, 
total protein loss measured by this assay in our 
experiments was less than 25% in 240 h, indicating 
that loss of monomer is not simply caused by adsorp- 
tion of peptide to the test tubes or other surfaces 
during sample handling. In a second assay for protein 
aggregates with a molecular weight > 30 kDa, /3- 
sheets content was measured by the increase in 
Thioflavin T fluorescence in the supernatant after 
ultrafiltration through a 30kDa membrane. The in- 
crease in protein concentration measured both by 
Thioflavin T and Bradford (Coomassie Blue) of the 
supernatant after ultracentrifugation (aggregates > 30 
kDa) solely in the samples containing fructose show 
that the disappearance of monomer (by AGE cross- 
linking) is directly coupled to the gain of aggregates. 
Formation of /3-amyloid peptide aggregates was also 
visualized by Western blot using a specific poly- 
clonal antibody raised against he 1-40 peptide. Fi- 
nally, number and size of macroscopic peptide aggre- 
gates (> 6 /xm in diameter) were measured with a 
cell counter. 
13/A4 with fructose 13/A4 without fructose 
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Fig. 1. Loss of soluble /3-amyloid peptide (1-40) by glycation/AGE-crosslinking. 60 /zM /3-amyloid peptide in 50 mM sodium 
phosphate buffer, pH 7.9, was incubated at50°C without sugars (right gel) and with 50 mM fructose (left gel). After the times indicated, 
20 /xl of the sample (5 /~g of peptide) was added to 10 Izl SDS electrophoresis sample buffer and incubated at42°C for 30 min. The 
peptides were separated in a Tris/Tricine polyacrylamide geland stained with Coomassie Blue G-250. 
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3.2. Acceleration of ~-amyloid peptide aggregation 
by fructose mediated AGE-crosslinking 
/3-amyloid peptide (1-40) was incubated at a con- 
centration of 60 /zM with and without 50 mM fruc- 
tose at 50°C. In contrast o other peptides, i.e. neu- 
ropeptide Y (see Fig. 9) or model proteins like 
lysozyme, which show the characteristic oligomer 
'ladder' after AGE-crosslinking, crosslinking of /3- 
amyloid peptide (1-40) by fructose derived AGEs 
leads to a constant reduction of soluble monomer 
over time, similar to that described for glucose in- 
duced crosslinking [18], but with a much faster eac- 
tion rate (lag time: 18 h at 50 °C). Faint bands of 
peptide oligomers are visible at approximately 24 h 
(Fig. 1, lane 3), but cannot be detected at a later 
stage. It is possible, that the AGE-crosslinked /3- 
amyloid peptide oligomers are spread over a range of 
different molecular weights; thus the amount of pep- 
Top of 
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Fig. 2. Immunoblot of /3-amyloid aggregates. Western blot was 
performed using 1 /xg of /3-amyloid peptide incubated with 50 
mM fructose in 50 mM sodium phosphate buffer, pH 7.9. Whereas 
aggregates are not visible in freshly dissoved peptide (lane 2), a 
heterogeneous collection of aggregates can be detected after 36 h 
(lane 3), 72 h (lane 4) and 96 h (lane 5). In lane 1, molecular 
weight markers are shown. 
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Fig. 3. Timecourse of the disappearance of /3-amyloid monomer 
and formation of peptide aggregates > 30 kDa by AGE-mediated 
crosslinking. 60 /zM /3-amyloid peptide in 50 mM sodium 
phosphate buffer, pH 7.9, was incubated without sugars (open 
symbols) and with 50 mM fructose (filled symbols). /3-amyloid 
peptide incubated without sugar at 50°C shows no loss of 
monomer (open circles) and no formation of aggregates (open 
square), whereas disappearance of monomer (filled circles) and 
formation of aggregates (filled squares) was enhanced by fruc- 
tose. Experiments were performed in duplicate; data are shown as 
mean + S.E.M. 
tide in one oligomer band is below the sensitivity 
limit of the Coomassie stain assay. Immunoblotting 
was used as a more sensitive method to improve the 
detection of high molecular weight aggregates after 
36 h, where no oligomers can be detected in the gel 
by Coomassie staining. Immunoreactive /3-amyloid 
peptide aggregates could be detected below the bor- 
der of the spacer and the separating el; their amount 
decreases slowly during the timecourse of the reac- 
tion. In addition, a significant portion of the aggre- 
gates are compressed directly at the gel border, lead- 
ing to an apparent higher local peptide concentration 
(Fig. 2). However, one has to be careful with a 
quantitative interpretation, since adsorption of large 
aggregates and peptide monomer may be quite differ- 
ent. /3-amyloid peptide incubated without sugars 
seems to form aggregates ata much slower rate; thus 
the amount of soluble monomer is nearly constant for 
the first 72 h and no aggregates are formed during 
this time (Fig. 1). The loss of peptide monomer in the 
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Fig. 4. Formation of thioflavin binding fl-amyloid aggregates by 
AGE-crosslinking. fl-amyloid aggregates with a molecular weight 
above 30 kDa by crosslinking with 50 mM fructose was mea- 
sured with thioflavin T (as an indicator of fl-sheet content, filled 
triangles) and Coomassie Blue (Bradford assay; as an indicator of 
total protein content, filled circles) between 0 and 240 h. Experi- 
ments were performed in duplicate; data are shown as mean S 
S.E.M. 
samples containing fructose was accompanied by a 
parallel increase in peptide aggregates above 30 kDa. 
When the fl-amyloid peptide was incubated without 
fructose, both the disappearance of fl-amyloid 
monomer and the formation of aggregates > 30 kDa 
was marginal compared to the samples with fructose 
(Fig. 3). This is in agreement with the hypothesis of a 
cooperative aggregation model with an association 
constant of 1.05 × 10 4 mol- ~ [51], which is twice the 
peptide concentration used in our experiments. 
The /3-amyloid aggregates over 30 kDa were also 
measured by Thioflavin T binding, a method assumed 
to correlate with the fl-sheet content of the respective 
protein [18]. Interestingly, fl-sheet formation corre- 
lates well with the amount of peptide oligomers, 
indicating that the change of conformation, from 
random-coil of the monomer to /3-sheet of the 
oligomer, occurs parallel to crosslinking and 
oligomerisation (Fig. 4). In addition, Vasan et al have 
shown by electron microscopy in a very recent study 
that AGE-mediated crosslinking of fl-amyloid leads 
to formation of fl-sheeted fibrils [52]. 
Large peptide aggregates (in /xm size) were 
counted and analyzed in a cell counter (Fig. 5). The 
number of /3-amyloid aggregates and their total vol- 
ume is constant for the first 100 h, then increases 
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Fig. 5. Analysis of large fl-amyloid aggregates with a cell 
counter. AGE-/3-amyloid peptide aggregates with a diameter 
between 6 and 24/xm were counted in a cell counter, l0 /xl of 60 
/zM peptide solution were diluted in 10 ml 0.9% NaC1; the 
number of aggregates and their size distribution were analyzed in 
triplicate. The left chromatogram shows the typical background 
level of the counter, the middle picture the aggregate size distri- 
bution of an /3-amyloid/fructose sample at 0 h, the right chro- 
matogram after 180 h. 
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Fig. 6. Timecourse of the formation of large AGE-fl-amyloid 
aggregates. After subtraction of the background level of the 
counter, the number of AGE-/3-amyloid peptide aggregates (open 
circles) and their total volume (filled squares) are shown per/xl 
of 60 /zM peptide solution. Experiments were done in duplicate; 
data are shown as mean + S.E.M. 
between 100 and 240 h (Fig. 6). Interestingly, a 
significant number of seeds is already present in a 
freshly dissolved /3-amyloid peptide solution. How- 
ever, this assay has to interpreted very cautiously, 
since light microscopy shows also fibrillary assem- 
blies, which may not be counted accurately. 
In summary, among the different assays to monitor 
covalent crosslinking of the /3-amyloid peptide by 
AGEs, the disappearance of the 4.2 kDa band of the 
monomer was the earliest indication for occurrence 
of crosslinking; hence this assay was used for the 
following experiments. 
h at 50°C). The lag time decreased from 52 h to 32 h, 
when the concentration of fructose was raised from 
50 mM to 200 mM, indicating a faster glycation and 
subsequent nucleus formation of the peptide. The 
similar slope of the growth curve indicates that, after 
the glycation steps were completed, the growth of the 
aggregate depends mainly on the inherent cross- 
linking reactivity of the bound AGE. This indicates, 
that the protein bound Amadori products are the 
predominant precursors for the crosslinking reaction, 
as recently reported for collagen in phosphate con- 
taining buffers [50]. 
3.4. Attenuation of seed formation and plaque growth 
by AGE-inhibitors 
Attenuation of /3-amyloid peptide aggregation and 
plaque formation is considered one of the prime 
targets of drug development for Alzheimer's disease. 
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3.3. Influence of temperature and different fructose 
concentrations on aggregation parameters 
Having established the accelerating effect of fruc- 
tose on /3-amyloid nucleation and aggregate growth, 
this reaction was investigated further. For this pur- 
pose, different fructose concentrations (50 mM vs. 
200 mM) and different temperatures (40°C vs. 50°C) 
were used (Fig. 7). At 40°C, the crosslinking reac- 
tion, measured by the disappearance of soluble 
monomer, was significantly slower (52 h at 40°C, 18 
t ime (h) 
Fig. 7. Acceleration of AGE-mediated /3-amyloid monomer 
crosslinking by increased fructose concentrations. 20 /~g of 
fl-amyloid peptide was incubated in 80 /a.1 50 mM sodium 
phosphate buffer, pH 7.9, at 40°C without sugars (filled circles), 
50 mM fructose (open circles) and 200 mM fructose (hatched 
squares). After 22, 48 and 110 h, samples containing 5 /zg of 
/3-amyloid peptide were taken and the percentage of soluble 
monomer was quantified by densitometric scanning of the 
Coomassie Blue G-250 stained band after gel electrophoresis. 
Experiments were performed in duplicate; data are shown as 
mean + S.E.M. 
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Fig. 8. Inhibition of AGE-mediated /3-amyloid peptide cross- 
linking by the AGE-inhibitor Tenilsetam. 20 /xg of /3-amyloid 
peptide was incubated in 80/xl 50 mM sodium phosphate buffer, 
pH 7.9, at 40°C without sugars (filled circles), 50 mM fructose 
(open circles) and 50 mM fructose + 50 mM Tenilsetam (hatched 
squares). After 22, 48 and 110 h, samples were taken and the 
percentage of soluble monomer left in the supernatant quantified 
by scanning of the Coomassie Blue G-250 stained band after gel 
electrophoresis. Experiments were performed in duplicate; data 
are shown as mean + S.E.M. 
Inhibition of AGE-mediated /3-amyloid crosslinking 
is a promising therapeutic strategy with the potential 
to slow down 13-amyloid plaque formation and the 
progression of the disease [44]. One AGE-inhibitor of 
demonstrated clinical benefit in Alzheimer's disease, 
Tenilsetam, was shown to inhibit glycation and 
AGE-mediated crosslinking of model proteins [20]. 
Incorporation of Tenilsetam into glycated, but only 
marginally into unmodified proteins suggests that it 
exerts its anti-crosslinking effect by capping reactive 
aldehyde groups on free and bound sugars [20]. To 
measure the effect of Tenilsetam on the timecourse of 
fructose induced crosslinking of /3-amyloid peptide, 
it was added in a 1:1 ratio (50 mM) to the reaction 
mixture and the time-course was followed for 110 h 
at 40°C. Seed formation (increased lag time) seems to 
be only minimally attenuated, whereas the growth of 
aggregate (loss of monomer/time) was slowed by 
more than 50% (Fig. 8). 
The experiments were extended to other known 
AGE-inhibitors. Aminoguanidine is a more reactive 
amine than the lysine eamino group and blocks the 
carbonyl group of the fructosyl moiety by covalent 
attachment [22]. Carnosine is a naturally occurring 
dipeptide with strong antioxidant, metal chelating and 
anti-glycation properties, most likely by mimicking 
the preferred glycation site on proteins [23]. It was 
also shown to rejuvenate and prolong the life span of 
diploid fibroblasts [43]. All three AGE crosslinking 
inhibitors (aminoguanidine, carnosine and Tenilse- 
tam, Fig. 9) were compared in a system containing 60 
/zM /3-amyloid peptide and 50 mM fructose for 24 h 
at 50°C. To demonstrate hat the inhibitory effect on 
crosslinking is a general effect, a control peptide with 
a similar molecular weight, neuropeptide Y, was 
included. Whereas NPY showed the typical oligomer 
ladder, /3-amyloid peptide incubated without AGE- 
o 
aminog uanidine carnosine t enilset am 
Fig. 9. Chemical structures of the AGE-inhibitors aminoguanidine, carnosine and Tenilsetam. 
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Fig. 10. Comparison of inhibition of AGE-mediated /3-amyloid peptide and neuropeptide Y crosslinking by AGE-inhibitors. /3-amyloid 
peptide and NPY (5 /xg of peptide in 20 /zl 50 mM sodium phosphate buffer, pH 7.9) were incubated with 50 mM fructose (lanes 1, 5), 
50 mM fructose + 50 mM aminoguanidine (lane 2, 6), 50 mM fructose + 50 mM carnosine (lane 3, 7) and 50 mM fructose + 50 mM 
Tenilsetam (lane 4, 8) for 24 h at 50°C. Whereas /3-amyloid peptide oligomers (lanes 1-4) precipitate, distinct soluble NPY oligomers 
(lanes 5-8) are visible under the same conditions. 
inhibitors showed the characteristic disappearance of
soluble monomer. All three AGE-inhibitors prevented 
crosslinking of both peptides ignificantly, and nearly 
100% of the /3-amyloid peptide was kept in solution 
(Fig. 10). However, it has to be noted that this 
experiment utilized a peptide batch from a commer- 
Q slow 
fast 
S 
fast# 
Fig. 11. Mechanism of nucleation dependent polymerization. 
Aggregation of the /3-amyloid peptide monomer follows the 
mechanism of nucleation dependent polymerization, i  which the 
slow formation of a nucleus from peptide monomers was subse- 
quently followed by a rapid growth phase as soon as the seed is 
formed. 
cial source (Auspep), which already contains a small 
amount of crosslinked /3-amyloid peptide dimer. 
4. Discussion 
4.1. /3-amyloid peptide in plaque formation and in 
Alzheimer's disease 
An unequivocal causal relationship between /3- 
amyloid formation and Alzheimer's disease has not 
been proven so far. However, significant genetic and 
biochemical evidence supports the hypothesis that 
/3-amyloid peptide is involved in the etiology or 
progression of the disease [6,9,24,25]. Since age is 
the major risk factor in Alzheimer's disease [42], the 
time-course of these aggregation processes is the key 
to understanding the progress of the disease as well 
as the therapeutic opportunities for its treatment. 
Lansbury and coworkers proposed that aggregation 
of the/3-amyloid peptide occurs by nucleation-depen- 
dent polymerization, a process similar to that seen in 
such as protein crystallization and microtubule forma- 
tion [16]. The process consists of an initial slow 
nucleus formation followed by a subsequent rapid 
growth phase (Fig. 11). Formation of the nucleus 
requires a series of association steps that are thermo- 
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dynamically unfavorable and only occur in supersatu- 
rated solutions, because the energy gain of the associ- 
ation has to be greater than the entropic osts. Since 
these association steps are reversible, crosslinking of 
the monomers, which prevents the dissociation of the 
formed oligomers, could facilitate the formation of a 
nucleus at low physiological peptide concentrations. 
Once the nucleus is formed, further attachment of 
monomers to the preformed seed at multiple binding 
sites leads to rapid growth of the aggregate [16]. 
Both steps of this polymerization process are ac- 
celerated by crosslinking of monomers through AGEs. 
The /3-amyloid peptide contains four major cross- 
linking sites, for AGEs in its sequence (two lysines, 
one arginine and the N-terminal amino group), allow- 
ing the formation of a three-dimensional network. 
The first step, the formation of the nucleus, is signifi- 
cantly shortened by crosslinking of the monomers by 
AGEs, with fructose being much more reactive than 
glucose. Increased concentration f sugar accelerates 
the formation of a seed, supporting the hypothesis 
that crosslinking of the /3-amyloid peptide by AGEs 
is the crucial step for formation of a stable nucleus. 
For the second step, the growth of the plaque from 
a preformed seed, AGE-modified seeds are faster 
reacting nuclei for /3-amyloid peptide aggregation 
than non-modified AGE seeds [18]. We have shown 
that fructose significantly accelerates the growth of 
the plaque from a preformed seed in comparison with 
glucose. However, under these experimental condi- 
tions the reaction rate for the aggregate growth is 
independent of fructose concentration. This suggests 
that the growing aggregate is saturated with cross- 
linking-reactive AGEs, which are able to covalently 
bind additional peptide monomers. Therefore, after 
the amino groups of the peptide are completely gly- 
cated, the conversion of the Amadori products to 
reactive AGEs might be the rate determining steps 
for the growth of the aggregate. 
In most studies, aggregation experiments with syn- 
thetic amyloid peptides utilized supersaturated solu- 
tions. In order to obtain a reasonable amount of 
AGE-crosslinked protein in a reasonable time period, 
we have worked with high concentrations of both 
peptide and sugars. However, under physiological 
conditions, AGE-modification of proteins yields a 
substantial mount of crosslinked proteins only after 
a long time span, in the range of months or even 
years [38], which is similar to the late onset and 
slowly progressive nature of Alzheimer's disease. 
Nevertheless, these experiments provide a basis for 
the planning of long-term studies under physiological 
conditions. Since the first step, the glycation of the 
primary amine, is a simple bimolecular chemical 
reaction, the reaction rate is proportional to concen- 
trations of both partners (v = k X [sugar] X [protein]) 
[39]. Therefore, glucose concentrations up to 1M and 
protein concentrations up to 50 mg/ml  are generally 
used in AGE studies to accelerate he reaction [26,27]. 
In Alzheimer's disease, the average of the plaque 
proteins, measured by amino acid racemization, was 
estimated to be at least 20 years [28]. In this time 
frame, covalent crosslinking of peptide monomers i
necessary to allow nucleation and growth in physio- 
logical, non-supersaturated peptide solutions, when 
self aggregation is thermodynamically unfavorable 
[5i]. 
4.2. Contribution of  fructose to AGE-mediated cross- 
linking in the brain 
Previous crosslinking experiments with /3-amyloid 
peptide have used glucose, the major energy source 
in the brain [18]. However, crosslinking by glucose 
under non-oxidative conditions is extremely slow. 
Glycoxidation products, which are produced by tran- 
sition metal-mediated oxidation of soluble and pro- 
tein bound sugars have therefore been proposed to be 
the reactive species [29]. Since our experiments were 
also performed under oxidative conditions, we sug- 
gest a significant crosslinking of /3-amyloid peptide 
by fructose in vivo via a mechanism similar to that 
proposed for glucose [30]. 
In human plasma which has a glucose concentra- 
tion of approximately 4-5 mM and fructose concen- 
tration of approximately 0.2 mM (ratio > 20:1), 
about 15% of the plasma proteins are glycated by 
fructose [21], indicative of the higher glycation reac- 
tivity of this sugar. However, in human brain, the 
glucose/fructose ratio is reduced from 20 to about 4 
(glucose 2 mM, fructose 0.5 mM), consistent with the 
proposed higher contribution of fructose to AGE- 
crosslinking in the brain than in peripheral systems 
[21]. One might speculate that changes in the concen- 
tration of fructose or other AGE reactive sugars 
should have a significant effect on peptide glycation 
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and subsequently on the time-course of plaque forma- 
tion in vivo. In ongoing studies, we are preparing 
fructose-AGE antibodies to identify these compounds 
in post mortem tissue. The involvement of sugars 
other than glucose in AGE crosslinking might be a 
interesting link to another characteristic feature of 
Alzheimer's disease, the disturbance of the cerebral 
glucose metabolism [32]. 
4.3. AGEs, diabetes and Alzheimer's disease 
AGEs have been shown to play an important role 
in the evolution of vascular complications in normal 
aging, more so in diabetes and renal failure. In 
diabetes, accelerated AGE accumulation is caused by 
a higher level of plasma glucose and, intracellularly, 
by the activation of the polyol pathway and in 
hemodialysis by the inability of the dialysis car- 
tridges to remove AGE-modified peptides [46,47]. In 
AD, other factors are required to explain the elevated 
level of AGEs and AGE-crosslinked proteins. 
Interestingly, there is no increased risk of AD in 
diabetic patients. This might be due to several rea- 
sons: Dementia in patients with diabetes is likely to 
be a vascular type dementia, which statistically in- 
creases the number of AD patients in the non-diabetic 
group. Further, diabetic patients do not have a greater 
risk of accumulating AGEs in the brain, since the 
brain glucose level of diabetic patients is not in- 
creased. In contrary, the transport capacity for glu- 
cose across the blood brain barrier is reduced, most 
likely resulting from downregulation of the glucose 
transporters [48]. On the other hand, Alzheimer's 
disease patients do not show an increased AGE level 
in plasma [49], again suggesting that cerebral AGE 
accumulation i Alzheimer's disease is a very selec- 
tive, brain specific event. 
cated proteins and acts as an inhibitor of AGE-de- 
rived protein crosslinking in vitro. Carnosine, the 
third AGE-inhibitor tested, is classified as an antioxi- 
dant, a metal-chelator as well as an anti-glycation 
agent [23,31]. In general, AGE-inhibitors can exert 
their effects at different levels of the glycation cas- 
cade (Maillard reaction). Continuous capping of reac- 
tive AGEs on growing amyloid plaques is one of the 
explanations of the clinical effects of the AGE-inhibi- 
tor Tenilsetam [20]. This can feasibly be extended to 
the inhibition of AGE-mediated microtubule associ- 
ated protein tau crosslinking in neurofibrillary tangle 
formation [35]. 
In this study, Tenilsetam could significantly inhibit 
the growth of the /3-amyloid peptide aggregate by 
nucleation-dependent polymerization. The other 
AGE-inhibitors were similarly effective in keeping 
the /3-amyloid peptide in its soluble monomeric form. 
For both proposed mechanisms of neuronal cell death, 
direct or indirect oxicity of the /3-amyloid peptide, a 
decreased formation of toxic peptide aggregates may 
be therapeutic. It is also be possible that AGE-inhibi- 
tors modify the structure of AGEs in a way that 
causes a loss of their binding to cell surface AGE-re- 
ceptors. This could lead to a diminished inflamma- 
tory response and decreased oxidative stress [40,41]. 
These hypotheses provide a speculative but reason- 
able explanation for the clinical effects seen with 
Tenilsetam in patients with Alzheimer's disease, 
where cognitive abilities and memory improve slowly 
over a time span of three months [19,20]. However, a 
direct attenuation of cytotoxic AGE effects by AGE- 
inhibitors has to be shown at least before proposing 
this as a valid approach for the treatment of AD 
patients. 
4.5. Physiological role of AGE-inhibitors 
4.4. AGE-inhibitors as neuroprotective drugs 
AGE mediated protein crosslinking can be inhib- 
ited by aminoguanidine, the prototype of an AGE-in- 
hibitor not only in vitro, but also in vivo as seen in 
the prevention of vascular complications of diabetes 
[33,34]. Tenilsetam, a cognition-enhancing and anti- 
dementia drug was also shown to be an effective 
AGE-inhibitor without any radical scavenging prop- 
erties [19,20]. Tenilsetam reacts with sugars and gly- 
One of the obvious disadvantages of AGE-inhibi- 
tors in regard to their biological significance and 
therapeutic efficacy is, that relatively high concentra- 
tions (in a equimolar atio to sugars) seem to be 
required for an effective inhibition of AGE-forma- 
tion. This is the result of the underlying chemical 
stochiometry of the Maillard reaction. However, when 
sugars more reactive than glucose with a lower 
physiological concentration are taken into considera- 
tion, a 1:1 ratio of AGE-inhibitor and sugar might be 
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achieved. In tissues such as muscle and olfactory 
tissue the physiological AGE-inhibitor carnosine and 
related substances reach a concentration of up to 50 
mM [36]. It is likely that mammals have developed 
strategies to minimize glycation and AGE-formation 
as a defense mechanism using physiological AGE-in- 
hibitors [23]. Dysfunction of the physiological AGE- 
defense and clearance mechanisms may be an expla- 
nation for a variety of degenerative diseases. On the 
other hand, supplementing aturally occurring anti- 
glycation molecules by synthetic drugs like Tenilse- 
tam, especially in tissues with low concentrations of 
natural AGE-inhibitors may be a promising therapeu- 
tic strategy not only for Alzheimer's disease, but also 
for various AGE-mediated egenerative and AGE-re- 
lated diseases. 
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